EICHOR

Recruiting studies: Relapsed Refractory Solid Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Phase 1 · 3 location(s) · Stingray Therapeutics · NCT06063681 A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come
Phase 1 · 5 location(s) · Memorial Sloan Kettering Cancer Center · NCT04928677 Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and So
Phase 1 · 1 location(s) · Lantern Pharma Inc. · NCT06132503 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994 A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Phase 1 · 8 location(s) · FBD Biologics Limited · NCT05892718 VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Phase 1/Phase 2 · 7 location(s) · University of Texas Southwestern Medical Center · NCT04796012 An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
EARLY_Phase 1 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05166070 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871 A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
Phase 1 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06730659 Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced
NA · 1 location(s) · Wuxi People's Hospital · NCT06430502 A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBE
Phase 1/Phase 2 · 17 location(s) · Merck Sharp & Dohme LLC · NCT07630974 SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid
Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT06936748 Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Phase 1 · 4 location(s) · InSilico Medicine Hong Kong Limited · NCT06445517 Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
Phase 1 · 1 location(s) · CytoMed Therapeutics Pte Ltd · NCT05302037 Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825 SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid T
Phase 1 · 11 location(s) · Qurgen Inc. · NCT06873659 Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06150365 KSH01-TCRT Solid Tumors
EARLY_Phase 1 · 1 location(s) · TCRx Therapeutics Co.Ltd · NCT05539833 Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SG
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT05521984 Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Phase 1 · 1 location(s) · New York Medical College · NCT04308330 Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07492628 Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494 Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Soli
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT06620302 Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Phase 1 · 11 location(s) · ImmunoGenesis · NCT06014502 NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
Phase 1 · 1 location(s) · Henan Medical University · NCT05528341 Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480213 Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Phase 1/Phase 2 · 1 location(s) · University of Florida · NCT06625190 Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07598955 Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors
Phase 1 · 1 location(s) · Chulalongkorn University · NCT06612645

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →